Operating margin rebounds to 25.46% as revenue growth outpaces costs
Revenue grew 19.10% year on year, while management said its rural programme reached seven states and tested more than 100,000 patients.
Filed 24 Jul 2026, 13:37 IST · Dr Lal Pathlabs Ltd (LALPATHLAB)
Key takeaways
- Consolidated operating margin rose 1.92 percentage points year on year to 25.46% as revenue grew 19.10%, faster than expenses at 16.11%.
- Net profit increased 27.24% year on year to Rs 170.5 cr, but basic EPS declined 36.08% to Rs 10.15.
- The stock rose 5.21% after the results, exceeding its 2.19% median absolute move after the past eight result announcements.
Price around the results
Revenue growth lifted operating profit
Consolidated revenue rose 19.10% year on year to Rs 797.7 cr, while operating profit grew 28.79% to Rs 203.1 cr. Expenses increased 16.11%, slower than revenue, which lifted operating margin by 1.92 percentage points. Sequentially, revenue growth accelerated to 13.52% and operating margin improved 5.22 percentage points from Q4FY26.
Margin recovery came with higher tax and interest costs
The tax rate rose 8.02 percentage points sequentially to 25.45%, yet profit before tax increased 42.85% because revenue growth outpaced expense growth. Interest expense was also 34.04% higher year on year. Other income contributed 13.95% of pre-tax profit, so reported earnings included a meaningful non-operating contribution.
Margin has recovered from a two-quarter decline
Operating margin had fallen from 25.13% in Q2FY26 to 20.79% in Q3FY26 and 20.24% in Q4FY26 before recovering to 25.46% in Q1FY27. The company was 0.82 percentage points above the 24.64% median margin of the eight Healthcare peers that had reported the quarter. Management said balancing growth investments with profitability remains a competitive advantage.
Rural diagnostics programme expands its reach
Management said the company launched GraminFit as a scalable rural preventive healthcare programme for underserved diagnostics markets. It also said the programme had expanded to seven states and tested more than 100,000 patients in Q1FY27. These initiatives provide context for the quarter's growth focus without changing the reported margin outcome.
Market reaction was unusually positive for this stock
The stock rose 5.21% on the results date, with relative performance of 5.64%. That was larger than the 2.19% median absolute move seen across its past eight result reactions, during which the stock rose three times and fell five times.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹798 cr | ₹703 cr | +13.52% | +19.10% |
| Other income | ₹32 cr | ₹24 cr | +32.92% | +13.52% |
| Expenses | ₹595 cr | ₹561 cr | +6.08% | +16.11% |
| Operating profit | ₹203 cr | ₹142 cr | +42.83% | +28.79% |
| Operating margin (%) | 25.46% | 20.24% | — | — |
| Interest | ₹6 cr | ₹6 cr | +3.28% | +34.04% |
| Depreciation | ₹44 cr | ₹45 cr | -0.45% | +28.32% |
| Profit before tax | ₹229 cr | ₹160 cr | +42.85% | +26.28% |
| Tax | ₹58 cr | ₹28 cr | +108.60% | +23.57% |
| Net profit | ₹171 cr | ₹132 cr | +28.97% | +27.24% |
| EPS (₹) | ₹10.15 | ₹7.86 | +29.13% | -36.08% |
Operating margin of 25.46% compares with a Healthcare sector median of 24.64% across 8 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +5.21% | +5.64% |
Volume on the results session was 4.66× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company tested more than 100,000 patients through its rural outreach programme in Q1 FY27.
New initiatives
- The company launched GraminFit, a scalable rural preventive healthcare programme targeting underserved diagnostics markets.
- The rural preventive healthcare programme has expanded to seven states.
Competition
- Management described balancing growth investments with profitability as a key competitive advantage.
What to watch
- Whether operating margin holds above 25.46% after the Q1FY27 rebound.
- Whether expense growth remains below revenue growth of 19.10%.
- The reach of GraminFit beyond the seven states reported in Q1FY27.